GERN Geron Corporation

2.55
+0  (6%)
Previous Close 2.40
Open 2.42
Price To book 3.12
Market Cap 405.85M
Shares 159,158,000
Volume 2,630,841
Short Ratio 22.82
Av. Daily Volume 1,780,770

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal review conducted September 2016, trial to continue as planned. Internal review due 2Q 2017.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data.
Imetelstat - IMbarkStudy
Myelofibrosis

Latest News

  1. Geron 2017 Annual Meeting of Stockholders to be Held on May 9
  2. Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron
  3. Geron’s Imetelstat Reports Positive Interim Data
  4. Why Geron Corporation Stock Is Surging Higher Today
  5. Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
  6. Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time
  7. ETFs with exposure to Geron Corp. : April 7, 2017
  8. Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : April 6, 2017
  9. Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
  10. ETFs with exposure to Geron Corp. : March 27, 2017
  11. Today's Research Reports on Stocks to Watch: Geron and Galena Biopharma
  12. Geron Corp. :GERN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  13. Geron Corp. :GERN-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  14. Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : March 15, 2017
  15. Edited Transcript of GERN earnings conference call or presentation 1-Mar-17 9:30pm GMT
  16. Geron Announces Presentation at American Association for Cancer Research Annual Meeting
  17. Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results
  18. Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2016 Financial Results
  19. 4 Stocks Under $4 That Could Double
  20. Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys